TY - JOUR TI - Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party AU - Schetelig, Johannes AU - Chevallier, Patrice AU - van Gelder, Michel AU - Hoek, Jennifer AU - Hermine, Olivier AU - Chakraverty, Ronjon AU - Browne, Paul AU - Milpied, Noel AU - Malagola, Michele AU - Socié, Gerard AU - Delgado, Julio AU - Deconinck, Eric AU - Damaj, Ghandi AU - Maury, Sebastian AU - Beelen, Dietrich AU - Quoc, Stéphanie Nguyen AU - Shankara, Paneesha AU - Brecht, Arne AU - Mayer, Jiri AU - Hunault-Berger, Mathilde AU - Bittenbring, Jörg AU - Thieblemont, Catherine AU - Lepretre, Stéphane AU - Baldauf, Henning AU - de Wreede, Liesbeth C. AU - Tournilhac, Olivier AU - Yakoub-Agha, Ibrahim AU - Kröger, Nicolaus AU - Dreger, Peter T2 - Bone Marrow Transplantation AB - No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/del CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II–IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted. DA - 2020/10/02/ PY - 2020 DO - 10.1038/s41409-020-01069-w DP - www.nature.com SP - 1 EP - 9 LA - en SN - 1476-5365 ST - Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia UR - https://www.nature.com/articles/s41409-020-01069-w Y2 - 2020/10/02/22:47:44 ER -